# A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

> **NCT03639987** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 52 (actual)

## Conditions studied

- Cognitive Dysfunction
- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03639987
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-20
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-07-30
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639987, "A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03639987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*